オプションチェーンは、Firefly Neuroscienceの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Firefly Neuroscienceの市場センチメントを評価します。.

Firefly Neuroscience (NASDAQ:AIFF) 株価情報, オプションチェーン

Firefly Neuroscience

Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders.

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience Inc

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $80 to $76.

News

Price Target

Analyst Ratings

PTCT

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76

Canaccord Genuity analyst Austin Moeller maintains Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) with a Buy and maintains $6 price target.

BAER

Canaccord Genuity Maintains Buy on Bridger Aerospace Gr, Maintains $6 Price Target

Cantor Fitzgerald analyst Brett Knoblauch maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Overweight and lowers the price target from $15 to $14.

APLD

Cantor Fitzgerald Maintains Overweight on Applied Digital, Lowers Price Target to $14

Evercore ISI Group analyst James West downgrades Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) from Outperform to In-Line and lowers the price target from $64 to $41.

Downgrades

Evercore ISI Group Downgrades Noble Corp to In-Line, Lowers Price Target to $41

OS Therapies reiterates clinical and regulatory path in recurrent, fully respected osteosarcoma with lung metastases, an indication with no currently approved treatments.
 &nbsp;

OSTX

OS Therapies Says Phase 2b Clinical Trial Of OST-HER2 Achieves Primary Endpoint With Statistical Significance In Prevention Of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Interview

BlackRock CEO Larry Fink Says Don't Believe You'll See BlackRock In The Market Buying Whole Companies

Evercore ISI Group analyst James West downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Outperform to In-Line and lowers the price target from $48 to $39.

Evercore ISI Group Downgrades Helmerich & Payne to In-Line, Lowers Price Target to $39

WIIM

Bank of New York Mellon shares are trading higher following better-than-expected Q4 financial results.

SPRC

SciSparc Says It Is Granted 180-Day Extension Until July 14, 2025, By Nasdaq To Regain Compliance With Minimum Bid Requirement

GS: 3% &#x7C; <a href="https://www.benzinga.com//node/42999133">Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking &amp; Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%</a>
&nbsp;
VCEL: -12% &#x7C; <a href="https://www.benzinga.com//node/42997435">Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.</a>
&nbsp;
COMP: 11% &#x7C; <a href="https://www.benzinga.com//node/42998131">Compass shares are trading higher after the company raised its Q4 and FY24 guidance.</a>

Movers

Trading Ideas

COMP

VCEL

Market-Moving News for January 15th

AVXL

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

Seaport Global analyst Kenneth Zener upgrades KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) from Sell to Neutral.

Upgrades

Seaport Global Upgrades KB Home to Neutral

Prairie expects Average Daily Production: 7,000 – 8,000 barrels of oil equivalent per day (BOEPD), representing a ~300% increase year-over-year.
Prairie plans to actively pursue additional strategic acquisition opportunities, the completion of which will result in an update to guidance to reflect the enhanced scale and value of the Company.

Guidance

PROP

Prairie Operating Expects 2025 Net Income  Of $69M - $102M, Adjusted EBITDA Of $100M - $140M,

Earnings

Goldman Sachs Total Loans Increased 7% During The Year

QBTS

D-wave Quantum Inks Pact With Carahsoft Partner To Expand Distribution Of Quantum Computing Solutions To The Public Sector

Rosenblatt analyst Blair Abernethy maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and maintains $18 price target.

SVCO

Rosenblatt Maintains Buy on Silvaco Group, Maintains $18 Price Target

ZLAB

Zai Lab Highlights Topline Results For TIVDAK In China Subpopulation Of Global Phase 3 innovaTV 301 Trial In Patients With Recurrent or Metastatic Cervical Cancer

Contracts

STRM

Streamline Health Signs New Contract For Use Of eValuator With Deaconess Health System

Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking & Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%

D. Boral Capital analyst Jesse Sobelson maintains New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) with a Buy and maintains $2 price target.

HOVR

D. Boral Capital Maintains Buy on New Horizon Aircraft, Maintains $2 Price Target

Firefly Neuroscience files to sell 2.56M shares for holders

Bright Minds and Firefly Neuroscience collaborate for EEG data in receptor agonist study

Wall Street Lunch: Zero To 60 In 2.5 Seconds

Bright Minds Biosciences ($DRUG) has announced a collaboration with Firefly Neuroscience ($AIFF), an AI firm that devises innovative solutions to e...

Bright Minds Biosciences (DRUG) Partners with Firefly Neuroscience, Resulting in Stock Surge

Firefly Neuroscience reports Q3 results

Firefly Neuroscience ( ($AIFF) ) just unveiled an announcement. Firefly Neuroscience, Inc. sees a leadership change as David Johnson steps down as ...

Firefly Neuroscience Appoints Greg Lipschitz as Executive Chairman

Firefly Neuroscience (AIFF) announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of Dece...

Firefly Neuroscience appoints Lipschitz as Executive Chairman

Firefly Neuroscience ( ($AIFF) ) has provided an update. Firefly Neuroscience, Inc. has entered into a securities purchase agreement with Helena Sp...

Firefly Neuroscience Expands Financial Flexibility with New Agreements

Bright Minds Biosciences ($DRUG) is finishing 2024 as one of the best-performing small-cap stocks, posting a remarkable 2400% increase in the share...

Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase

Firefly Neuroscience (AIFF) announced the advancement of research to assess a patient's brain age, an estimation of the biological age of a person'...

Firefly Neuroscience announces advancement of research to assess brain age

AIFF

DRUG

LUMN

RACE

SAVE

Press Releases

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Markets

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Management

Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

Financing

Firefly Neuroscience Closes on Financing of up to $12.4 Million

Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition

Health Care

General

Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform

Innovative Stocks to Watch: PNPN.V, NMHI, PRSO, AIFF Leading Bold Industry Transformations – More Stocks Inside!

Comments

Firefly Neuroscience

Firefly Neuroscience (AIFF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル